Get the Stockscreener App
49.70
6.65%
3.10
After Hours:
49.71
0.010
+0.02%
Moderna Inc stock is traded at $49.70, with a volume of 12.12M.
It is up +6.65% in the last 24 hours and up +18.81% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$46.60
Open:
$46.985
24h Volume:
12.12M
Relative Volume:
1.04
Market Cap:
$19.42B
Revenue:
$3.14B
Net Income/Loss:
$-3.36B
P/E Ratio:
-5.693
EPS:
-8.73
Net Cash Flow:
$-4.03B
1W Performance:
+23.91%
1M Performance:
+18.81%
6M Performance:
+78.07%
1Y Performance:
+38.44%
1-Day Range:
$45.80
$50.46
1-Week Range:
$41.20
$50.46
52-Week Range:
$22.28
$55.20
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
49.70 | 18.21B | 3.14B | -3.36B | -4.03B | -8.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.27 | 119.47B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
782.38 | 83.75B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
847.26 | 52.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
339.37 | 44.12B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
354.48 | 39.73B | 4.98B | 69.60M | 525.67M | 0.5198 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna jumps as FDA agrees to review its mRNA flu vaccine after earlier setback - Quiver Quantitative
BioNTech sues Moderna over alleged patent infringement involving a Covid vaccine - marketscreener.com
Moderna (NASDAQ:MRNA) Shares Up 7.1%Time to Buy? - MarketBeat
Key facts: Moderna shares rise on flu vaccine review; BioNTech sues Moderna; Patent case setback for Moderna - TradingView
BioNTech sues Moderna for patent infringement over COVID-19 shots - BNN Bloomberg
BioNTech sues Moderna for patent infringement over COVID shots - TradingView
Moderna’s Covid Vaccine Targeted in New BioNTech Patent Suit (2) - Bloomberg Law News
Will vaccine regulatory uncertainty chill innovation? Pharma execs sound off. - Pharma Voice
Moderna Stock Jumps After FDA Reverses Course on Flu Shot - TradingView
First Look: Walmart beat, Meta trial, FDA eyes Moderna - GuruFocus
🎧 The Moderna Flu-Shot Drama - The Wall Street Journal
Moderna to Present at Upcoming Conferences in March 2026 - ACCESS Newswire
FDA agrees to review Moderna's mRNA flu vaccine after refusal-to-file - WEAR-tv
Thrivent Financial for Lutherans Has $345,000 Stake in Moderna, Inc. $MRNA - MarketBeat
FDA will review Moderna’s new flu shot after all - Morning Brew
Moderna’s new flu vaccine to undergo review by FDA | Health Watch - CBS News
Moderna says the FDA will consider its new flu shot after resolving a public dispute - Griffin Daily News
After Moderna Flu Vaccine, Is US FDA’s Accelerated Approval A Pathway Or A Pressure Valve? - Citeline News & Insights
Is Moderna Inc (MRNA) Set to Underperform? Analyzing the Factors Limiting Growth - GuruFocus
FDA Reverses Decision About Moderna Flu Vaccine - The Bulwark
🎧 The Moderna Flu Shot Drama - The Wall Street Journal
Barclays starts Moderna, Inc. (MRNA) neutral as biotech outlook improves - MSN
Stock Movers: eBay, Moderna, Vita Coco - Bloomberg
FDA’s abrupt flip-flop on Moderna’s mRNA flu shot highlights growing risks to drug-makers of investing in vaccines - The Conversation
Moderna Loses 2 Defenses In Patent Fight - GuruFocus
FDA reverses course, will review Moderna’s flu vaccine application - Honolulu Star-Advertiser
Market Today: Moderna rebounds; oil and gold jump - GuruFocus
3 Once-in-a-Decade Buying Opportunities - The Motley Fool
Moderna got a win from the FDA, but political headwinds remain a concern for vaccine makers - The Boston Globe
Moderna’s flu vaccine back in play as FDA shifts course on review - BioWorld MedTech
FDA Changes Mind, Will Review Moderna MRNA Flu Vaccine - Law360
F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine - The New York Times
FDA reverses course on Moderna flu shot - KNKX
Moderna Jumps Above 20-Day Moving Average on FDA Flu Vaccine Review. Should You Buy MRNA Stock Here? - Barchart.com
FDA backtracks on public feud with Moderna and agrees to review mRNA flu vaccine after initial rejection - Fortune
Moderna stock surges as FDA reverses course, agrees to review new flu shot - Yahoo Finance
AI for investors - MLQ.ai
US FDA reverses course, will review Moderna's flu vaccine application | Business Information & News | FE - Westlaw Today
Walmart earnings in focus, Caesars stock surges, Moderna FDA review - Yahoo Finance
Why Moderna (MRNA) Stock Is Trading Up Today - TradingView
Breaking news: The FDA reversed course and agreed to review Moderna’s application for the first mRNA-based flu vaccine under a revised approach, the company announced. In a rare move last week, the agency had declined to review the vaccine. - Facebook
FDA Reverses Course and Will Now Review Moderna’s Flu Shot - The Wall Street Journal
FDA Does 180 On Moderna Flu Vaccine, But Approval Would Come With A Catch - Citeline News & Insights
FDA plans review of Moderna flu vaccine for older adults - upi.com
FDA reverses course and will review Moderna’s mRNA-based flu vaccine - The Guardian
Moderna says FDA will now consider its new mRNA flu shot after initial refusal - PBS
Why Moderna Stock Just Popped - AOL.com
FDA reverses its stance on Moderna flu vaccine review - Medical Economics
FDA reverses course and will review Moderna’s mRNA flu shot, company says - KRDO
In reversal, US FDA will review Moderna's flu vaccine application - Yahoo Finance
FDA Makes U-Turn Again On Moderna New Flu Vaccine Review, Stock Soars - Benzinga
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.15%
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):